Why Hinge Health (HNGE) is on investors’ radar
Hinge Health (HNGE) has been drawing attention after recent trading, with the stock last closing at US$55.25 and posting double digit gains over the past month and past 3 months.
For investors tracking digital health, the company’s roughly US$4.3b market cap and annual revenue of US$646.34m, alongside a reported net loss of US$511.39m, provide context for thinking about risk and potential reward.
See our latest analysis for Hinge Health.
The recent 30 day share price return of 24.75% and 90 day share price return of 37.75%, alongside a 1 year total shareholder return of 37.57%, suggest momentum has been building as investors reassess growth prospects against ongoing losses.
If Hinge Health has put digital health back on your watchlist, it may also be worth scanning for other healthcare focused AI opportunities using the 34 healthcare AI stocks
With Hinge Health still loss making but reporting US$646.34m in revenue and trading below analysts’ average price target, investors are asking a key question: is there genuine upside left, or is the market already pricing in future growth?
Most Popular Narrative: 14.1% Undervalued
Hinge Health’s most followed valuation narrative pegs fair value at $64.29 per share, above the recent $55.25 close. On that view, the stock screens as undervalued.
Rapid adoption of AI across care delivery and internal operations, including Robin and engineering productivity tools, is increasing clinician throughput and product velocity. This trend may structurally improve operating leverage and net margins over time.
Curious what earnings path and margin shift need to show up for that fair value to hold up? The narrative leans on faster revenue compounding, rising profitability and a steeper valuation multiple than many healthcare stocks usually carry.
Result: Fair Value of $64.29 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, you also need to weigh risks, such as pressure on employer budgets that could curb demand or any regulatory pushback that slows Hinge Health’s AI rollout.
Find out about the key risks to this Hinge Health narrative.
Another way to look at Hinge Health
While the popular narrative points to a fair value of $64.29 and an undervalued stock, the current 6.6x P/S ratio is far richer than the US Healthcare industry average of 1.2x and peer average of 4x. It is also still above a 6.2x fair ratio, which raises the question of how comfortable you are paying that premium.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment this mixed, it makes sense to act quickly, review the facts for yourself, and see why some investors are focusing on 4 key rewards
Looking for more investment ideas?
Do not stop at a single stock. Use the Simply Wall St screener to spot fresh opportunities that match how you like to invest before others move first.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Hinge Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
